Henry Schein, Inc. (NASDAQ:HSIC) Shares Sold by Corient Private Wealth LLC

Corient Private Wealth LLC lessened its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 18.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 45,520 shares of the company’s stock after selling 10,106 shares during the quarter. Corient Private Wealth LLC’s holdings in Henry Schein were worth $3,150,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of HSIC. Brandes Investment Partners LP raised its stake in Henry Schein by 10.9% during the fourth quarter. Brandes Investment Partners LP now owns 9,367 shares of the company’s stock worth $648,000 after acquiring an additional 918 shares during the period. Essential Planning LLC. acquired a new stake in Henry Schein during the fourth quarter worth about $934,000. Sequoia Financial Advisors LLC raised its stake in Henry Schein by 7.2% during the fourth quarter. Sequoia Financial Advisors LLC now owns 6,109 shares of the company’s stock worth $423,000 after acquiring an additional 412 shares during the period. HighTower Advisors LLC raised its stake in Henry Schein by 242.9% during the fourth quarter. HighTower Advisors LLC now owns 43,347 shares of the company’s stock worth $3,000,000 after acquiring an additional 30,706 shares during the period. Finally, AGF Management Ltd. acquired a new stake in Henry Schein during the fourth quarter worth about $796,000. Institutional investors and hedge funds own 96.62% of the company’s stock.

Insiders Place Their Bets

In other Henry Schein news, CEO Bradford C. Connett sold 4,036 shares of the business’s stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $71.15, for a total transaction of $287,161.40. Following the completion of the transaction, the chief executive officer now owns 62,688 shares of the company’s stock, valued at $4,460,251.20. The trade was a 6.05 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Philip A. Laskawy sold 2,604 shares of the business’s stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $71.04, for a total transaction of $184,988.16. Following the transaction, the director now directly owns 24,805 shares of the company’s stock, valued at approximately $1,762,147.20. This represents a 9.50 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.14% of the company’s stock.

Henry Schein Stock Down 1.5 %

HSIC stock opened at $69.39 on Friday. The company has a current ratio of 1.42, a quick ratio of 0.82 and a debt-to-equity ratio of 0.46. Henry Schein, Inc. has a 1 year low of $63.67 and a 1 year high of $82.49. The company has a fifty day simple moving average of $74.82 and a 200 day simple moving average of $72.61. The firm has a market cap of $8.62 billion, a PE ratio of 28.56, a PEG ratio of 2.13 and a beta of 0.90.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, February 25th. The company reported $1.19 earnings per share for the quarter, missing analysts’ consensus estimates of $1.23 by ($0.04). The firm had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.25 billion. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The firm’s revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.66 EPS. Sell-side analysts anticipate that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have commented on HSIC. Mizuho began coverage on shares of Henry Schein in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $75.00 price target on the stock. UBS Group lowered their price objective on shares of Henry Schein from $83.00 to $80.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 26th. Jefferies Financial Group raised their price objective on shares of Henry Schein from $77.00 to $80.00 and gave the company a “hold” rating in a research note on Thursday, January 23rd. Wells Fargo & Company assumed coverage on shares of Henry Schein in a research report on Friday, February 14th. They issued an “equal weight” rating and a $80.00 price target on the stock. Finally, Bank of America upgraded shares of Henry Schein from an “underperform” rating to a “buy” rating and lifted their price target for the stock from $69.00 to $84.00 in a research report on Monday, January 6th. Six research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $81.10.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.